These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10378876)

  • 21. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
    Jiang X; Wang HY; Yu J; Ganea D
    Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.
    Yadav M; Goetzl EJ
    Ann N Y Acad Sci; 2008 Nov; 1144():83-9. PubMed ID: 19076367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of nociceptin/orphaninFQ secretion by immune cells and functional modulation of interleukin-2.
    Miller TR; Fulford AJ
    Peptides; 2007 Nov; 28(11):2243-52. PubMed ID: 17950489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection.
    Mathew RC; Cook GA; Blum AM; Metwali A; Felman R; Weinstock JV
    J Immunol; 1992 Jun; 148(11):3572-7. PubMed ID: 1588046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of mouse T-cell proliferation by CGRP and VIP: effects of these neuropeptides on IL-2 production and cAMP synthesis.
    Boudard F; Bastide M
    J Neurosci Res; 1991 May; 29(1):29-41. PubMed ID: 1653367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demonstration of immunoreactive vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus.
    Gomariz RP; Lorenzo MJ; Cacicedo L; Vicente A; Zapata AG
    Brain Behav Immun; 1990 Jun; 4(2):151-61. PubMed ID: 1975506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-1alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2-dependent production of interleukin-11 in rheumatoid synovial fibroblasts.
    Mino T; Sugiyama E; Taki H; Kuroda A; Yamashita N; Maruyama M; Kobayashi M
    Arthritis Rheum; 1998 Nov; 41(11):2004-13. PubMed ID: 9811056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.
    Delgado M; Ganea D
    Amino Acids; 2013 Jul; 45(1):25-39. PubMed ID: 22139413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes.
    Bellinger DL; Lorton D; Horn L; Brouxhon S; Felten SY; Felten DL
    Peptides; 1997; 18(8):1139-49. PubMed ID: 9396054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA.
    Johnson MC; McCormack RJ; Delgado M; Martinez C; Ganea D
    J Neuroimmunol; 1996 Aug; 68(1-2):109-19. PubMed ID: 8784267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of VIP gene expression in general. Human lung cancer cells in particular.
    Davidson A; Moody TW; Gozes I
    J Mol Neurosci; 1996; 7(2):99-110. PubMed ID: 8873894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
    Sun W; Tadmori I; Yang L; Delgado M; Ganea D
    J Neuroimmunol; 2000 Jul; 107(1):88-99. PubMed ID: 10808055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
    Delgado M; Reduta A; Sharma V; Ganea D
    J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of mitogen-stimulated proliferation of murine splenocytes by a novel neuropeptide, pituitary adenylate cyclase activating polypeptide: a comparative study with vasoactive intestinal peptide.
    Tatsuno I; Gottschall PE; Arimura A
    Endocrinology; 1991 Feb; 128(2):728-34. PubMed ID: 1989859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4.
    Cunha FQ; Poole S; Lorenzetti BB; Veiga FH; Ferreira SH
    Br J Pharmacol; 1999 Jan; 126(1):45-50. PubMed ID: 10051119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction and expression of beta-calcitonin gene-related peptide in rat T lymphocytes and its significance.
    Xing L; Guo J; Wang X
    J Immunol; 2000 Oct; 165(8):4359-66. PubMed ID: 11035072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-1 stimulates interleukin-6 release from rat anterior pituitary cells in vitro.
    Spangelo BL; Judd AM; Isakson PC; MacLeod RM
    Endocrinology; 1991 Jun; 128(6):2685-92. PubMed ID: 2036955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
    Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP
    J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitogen-induced IL-2 production and proliferation at defined stages of T helper cell development.
    Chang JF; Thomas CA; Kung JT
    J Immunol; 1991 Aug; 147(3):860-6. PubMed ID: 1830601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.